Liver transplantation and vascular tumours

Transpl Int. 2010 Jul;23(7):686-91. doi: 10.1111/j.1432-2277.2010.01107.x. Epub 2010 May 14.

Abstract

Based on analysis of the literature and of the audited ELITA (European Liver Intestinal Transplant Association)-ELTR (European Liver Transplant Registry) data, the place of liver transplantation (LT) in the treatment of vascular tumours is discussed. Hepatic epithelioid haemangioendothelioma has currently become a good indication for LT with 5- and 10-year post-LT patient survival rates of 83% and 74% respectively and 5- and 10-year recurrence-free survival rates of 82% and 64% respectively. In contrast, the results of LT for haemangiosarcoma (HAS) are disastrous with an universal tumour recurrence within 6 months and no single patient survival after 2 years. Therefore, HAS remains an absolute contraindication to LT. The value of LT in the treatment of infantile haemangioendothelioma is more difficult to evaluate because of the very reduced number of reported cases and because of the often difficult differential diagnosis with angiosarcoma. LT should be reserved to those children not responding to medical treatment on the condition that sarcomatous modifications are excluded by expert pathologists to avoid a futile transplant procedure.

MeSH terms

  • Biopsy
  • Child, Preschool
  • Contraindications
  • Diagnostic Errors
  • Hemangioendothelioma, Epithelioid / surgery*
  • Hemangiosarcoma / mortality
  • Hemangiosarcoma / surgery*
  • Hepatectomy
  • Humans
  • Infant
  • Liver / pathology
  • Liver / surgery
  • Liver Neoplasms / surgery*
  • Liver Transplantation* / mortality
  • Neoplasm Recurrence, Local
  • Registries
  • Survival Rate
  • Vascular Neoplasms / surgery*